Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10217252 | 0.91 | PIK3CA (0.38) | MAPTPIK3CAPIK3CBPIK3CGPIK3CD | |
| SCHEMBL17613183 | 0.91 | PIK3CA (0.39) | MAPTPIK3CAPIK3CBPIK3CGPIK3CD | |
| SCHEMBL10173675 | 0.81 | PIK3CA (0.38) | MAPTPIK3CAPIK3CBPIK3CGPIK3CD | |
| SCHEMBL19628293 | 0.71 | PRKCZ (0.38) | MAPTALDH1A1KMT2ALMNA | |
| SCHEMBL903681 | 0.69 | PIK3CA (0.34) | MAPTPIK3CAPIK3CBPIK3CGPIK3CD | |
| SCHEMBL15806866 | 0.69 | PIK3CA (0.47) | MAPTPIK3CAPIK3CBPIK3CGPIK3CD | |
| SCHEMBL15804613 | 0.65 | PIK3CA (0.34) | PIK3CAPIK3CBPIK3CGPIK3CD | |
| SCHEMBL30715508 | 0.59 | APP (0.38) | MAPTLMNAHTTBLM | |
| SCHEMBL13191932 | 0.58 | GABRG2 (0.43) | MAPTPIK3CAPIK3CBPIK3CGPIK3CD | |
| SCHEMBL23440356 | 0.57 | PIK3CA (0.51) | MAPTPIK3CAPIK3CBPIK3CGPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356182-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2022-11-10 | — | — | US | disclosed |
| US-20190127365-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2019-05-02 | — | — | US | disclosed |
| US-20170008906-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008906-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| EP-2410844-B1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME (US) | 2016-03-23 | — | — | EP | disclosed |
| US-20150246917-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2015-09-03 | — | — | US | disclosed |
| US-20150246917-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2015-09-03 | — | — | US | disclosed |
| US-9090661-B2 | Inhibitors of hepatitis C virus replication | MERCK SHARP & DOHME CORP. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090661-B2 | Inhibitors of hepatitis C virus replication | MERCK SHARP & DOHME CORP. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140371138-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2014-12-18 | — | — | US | disclosed |
| US-20140371138-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2014-12-18 | — | — | US | disclosed |
| US-8871759-B2 | Inhibitors of hepatitis C virus replication | MERCK SHARP & DOHME CORP. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871759-B2 | Inhibitors of hepatitis C virus replication | MERCK SHARP & DOHME CORP. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20120083483-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP (NJ) | 2012-04-05 | — | — | US | disclosed |
| US-20120083483-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP (NJ) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083483-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | MAPT 4456/4885PIK3CA 2253/4885PIK3CB 1306/4885 |
| US-20140371138-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | MAPT 4456/4885PIK3CA 2253/4885PIK3CB 1306/4885 |
| US-20170008906-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | MAPT 4456/4885PIK3CA 2253/4885PIK3CB 1306/4885 |
| US-20150246917-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | MAPT 4456/4885PIK3CA 2253/4885PIK3CB 1306/4885 |
| US-20190127365-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | MAPT 4456/4885PIK3CA 2253/4885PIK3CB 1306/4885 |
| US-20220356182-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | MAPT 4456/4885PIK3CA 2253/4885PIK3CB 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.